Novartis to divest the Sandoz US dermatology business and generic US oral solids portfolio

11 Sep 2018

The Sandoz US portfolios to be sold to Aurobindo include approximately 300 products, as well as additional development projects.

Novartis has agreed to sell selected portions of its Sandoz US portfolio, specifically the Sandoz US dermatology business and generic US oral solids portfolio, to Aurobindo Pharma USA, for $0.9 billion of cash plus $0.1 billion of potential earn-outs. This transaction supports the Sandoz strategy of focusing on complex generics, value-added medicines and biosimilars to achieve sustainable and profitable growth in the US over the long-term.

Novartis to divest the Sandoz US dermatology business and generic US oral solids portfolio

The Sandoz US portfolios to be sold to Aurobindo include approximately 300 products, as well as additional development projects. The sale includes the Sandoz US generic and branded dermatology businesses, and its dermatology development center. As part of the transaction, Aurobindo will acquire the manufacturing facilities in Wilson, North Carolina, as well as Hicksville and Melville, New York. The business had net sales of $0.6 billion in H1, 2018.

"Sharpening our portfolio focus in the US allows us to devote more time and resources toward our strategy of bringing complex generics, value-added medicines and biosimilars to patients in the US, creating higher value and opening up access to important medicines where alternatives are truly needed," says Richard Francis, CEO Sandoz and Member of the Novartis Executive Committee. "Through this transaction, we are refocusing our business but also striving to ensure continuity of supply of important long-used generic medicines for patients and customers in the US."

As part of the agreement, approximately 750 employees in Hicksville, Melville, Wilson and Princeton, New Jersey, as well as the field representatives for the PharmaDerm branded dermatology business, are expected to transfer to Aurobindo upon closing. "We recognize that the transfer of ownership for a business of this size is a complex process, and we are aware that it may create some uncertainties for our associates in the US. It is thus a priority for us to make the transition as clear and quick as possible", says Carol Lynch, President of Sandoz Inc. and Head of Sandoz North America.

Following the transaction, the Sandoz US portfolio will continue to be substantial, and will include biosimilars, value-added medicines and complex generics such as injectables, respiratory and ophthalmics. Sandoz will continue to focus its clinical development, business development and investment efforts on these areas.

Read More

Related news

BIA Separations expands with new upstream processing facility

BIA Separations expands with new upstream processing facility

20 Sep 2018

Provides single source of expertise for scaled production of complex biologics for gene therapy and vaccines.

Read more 
Sanofi to refocus two global business units

Sanofi to refocus two global business units

19 Sep 2018

The new Primary Care and China & Emerging Markets global business units are expected to launch at the beginning of 2019.

Read more 
Experts warn trade and patent changes could increase healthcare cost by $100bn over next 5 years

Experts warn trade and patent changes could increase healthcare cost by $100bn over next 5 years

18 Sep 2018

China is harmonizing to ICH standards at feverish pace and will force poor quality manufacturers out of market.

Read more 
Recipharm connects to European Hub for serialisation compliance

Recipharm connects to European Hub for serialisation compliance

18 Sep 2018

Connection allows the marketing authorisation holders within the Recipharm Group to continue to supply medicines to patients post the EU FMD implementation date.

Read more 
Bosch to unveil new laboratory device for continuous manufacturing

Bosch to unveil new laboratory device for continuous manufacturing

18 Sep 2018

The Xelum R&D offers pharmaceutical manufacturers an ideal start to continuous OSD production.

Read more 
Partnership to deliver integrated, off-the-shelf biosimilar manufacturing solutions

Partnership to deliver integrated, off-the-shelf biosimilar manufacturing solutions

17 Sep 2018

Pall and Aetos to advance the market impact of biosimilars and deliver lower-priced, high-quality options to end users.

Read more 
Cambrex expands manufacturing footprint with acquisition

Cambrex expands manufacturing footprint with acquisition

16 Sep 2018

Completed acquisition adds formulation development and finished dosage manufacturing capabilities to Cambrex’s existing global API manufacturing network.

Read more 
NMPA approves fruquintinib capsules for metastatic colorectal cancer

NMPA approves fruquintinib capsules for metastatic colorectal cancer

13 Sep 2018

Fruquintinib - innovative medicine that has not previously been launched in China or internationally - provides a new therapeutic approach for metastatic colorectal cancer patients.

Read more 
Aptar Pharma to showcase an industry first

Aptar Pharma to showcase an industry first

12 Sep 2018

PureHale is a new portable drug delivery device designed for upper respiratory care.

Read more 
New SGS biopharmaceutical testing capabilities in Illinois

New SGS biopharmaceutical testing capabilities in Illinois

11 Sep 2018

The new services will focus on quality control analysis and stability testing of biopharmaceuticals.

Read more